English
Collaboration unites a worldwide leader in the clinical diagnostics industry with one of the nation’s top research and healthcare institutions to ideate solutions that will address today’s healthcare challenges
BREA, Calif. — (Oct. 16, 2018) — Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry, is embarking on an innovation collaboration with Johns Hopkins Medicine to explore co-innovation initiatives with the goal of developing and commercializing novel solutions that address challenges in healthcare.
For over a century, Johns Hopkins has enhanced research outcomes and advanced scholarship through the rigorous application of innovative methodologies and research approaches. For Beckman Coulter Diagnostics, this is an opportunity to learn from some of the best clinical minds in real-time and in a real-world setting.
Through this collaboration, Beckman Coulter will benefit from observing Johns Hopkins’ researchers and clinicians as they work to develop new technologies and concepts, which represent medical breakthroughs that can potentially help patients. Moreover, they will be able to test solutions on-site with experts who are working toward better patient care. Eventually, these solutions may be brought to market and could contribute to elevating healthcare throughout the nation.
“This collaboration allows us to define and solve problems with experts across clinical fields and situations, and allows us to work alongside top-notch researchers to develop smart solutions,” said John Blackwood, senior vice president and general manager of products and services, Beckman Coulter Diagnostics. “It is critical to explore and test new and innovative solutions with clinicians working in actual clinical settings to determine real-world quality and effectiveness. This will help us to address clinical challenges in a rapidly changing environment and foster our efforts to move healthcare forward for every person.”
Johns Hopkins’ faculty, students and start-up community are expected to benefit from Beckman Coulter Diagnostics’ expertise in global commercialization of diagnostic solutions. This should help accelerate the translational process from world-class research to healthcare application.
“Johns Hopkins is home to some of the most brilliant researchers in the world,” said Fiona Adair, Ph.D., vice president of strategy and innovation at Beckman Coulter Diagnostics. “We feel very confident that this collaboration will create an ‘innovation think tank’ that will lead to meaningful, long-lasting solutions that create insights to help implement value-based care.”
For over a century, Johns Hopkins has enhanced research outcomes and advanced scholarship through the rigorous application of innovative methodologies and research approaches. For Beckman Coulter Diagnostics, this is an opportunity to learn from some of the best clinical minds in real-time and in a real-world setting.
Through this collaboration, Beckman Coulter will benefit from observing Johns Hopkins’ researchers and clinicians as they work to develop new technologies and concepts, which represent medical breakthroughs that can potentially help patients. Moreover, they will be able to test solutions on-site with experts who are working toward better patient care. Eventually, these solutions may be brought to market and could contribute to elevating healthcare throughout the nation.
“This collaboration allows us to define and solve problems with experts across clinical fields and situations, and allows us to work alongside top-notch researchers to develop smart solutions,” said John Blackwood, senior vice president and general manager of products and services, Beckman Coulter Diagnostics. “It is critical to explore and test new and innovative solutions with clinicians working in actual clinical settings to determine real-world quality and effectiveness. This will help us to address clinical challenges in a rapidly changing environment and foster our efforts to move healthcare forward for every person.”
Johns Hopkins’ faculty, students and start-up community are expected to benefit from Beckman Coulter Diagnostics’ expertise in global commercialization of diagnostic solutions. This should help accelerate the translational process from world-class research to healthcare application.
“Johns Hopkins is home to some of the most brilliant researchers in the world,” said Fiona Adair, Ph.D., vice president of strategy and innovation at Beckman Coulter Diagnostics. “We feel very confident that this collaboration will create an ‘innovation think tank’ that will lead to meaningful, long-lasting solutions that create insights to help implement value-based care.”
